# Study of Multiple Doses of Saxagliptin (BMS-477118)

> **NCT00950599** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 423 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00950599
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950599, "Study of Multiple Doses of Saxagliptin (BMS-477118)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00950599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*